Recent positive Phase 3 results for the Merck-Moderna mRNA cancer vaccine (intismeran autogene) paired with Keytruda have reinforced their longstanding 2016 collaboration agreement, including Merck’s 2022 exercise of a $250 million joint-development option, rather than signaling any shift toward full ownership. Merck has pursued separate acquisitions such as Terns Pharmaceuticals and Verona Pharma to offset upcoming Keytruda patent losses and reach its $70 billion mid-2030s revenue target, while Moderna maintains independent operations amid its recent market-cap surge. With no regulatory filings, board disclosures, or strategic announcements indicating a 2026 deal, trader consensus prices the “No” outcome at 80.5% implied probability, reflecting the distinction between deepened partnership economics and outright M&A.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
20% โอกาส
ใหม่
ใหม่
Dec 31, 2026
20% โอกาส
ใหม่
ใหม่
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna mRNA cancer vaccine (intismeran autogene) paired with Keytruda have reinforced their longstanding 2016 collaboration agreement, including Merck’s 2022 exercise of a $250 million joint-development option, rather than signaling any shift toward full ownership. Merck has pursued separate acquisitions such as Terns Pharmaceuticals and Verona Pharma to offset upcoming Keytruda patent losses and reach its $70 billion mid-2030s revenue target, while Moderna maintains independent operations amid its recent market-cap surge. With no regulatory filings, board disclosures, or strategic announcements indicating a 2026 deal, trader consensus prices the “No” outcome at 80.5% implied probability, reflecting the distinction between deepened partnership economics and outright M&A.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: Aug 19, 2026, 3:58 PM ET
ปริมาณการซื้อขาย
$20วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results for the Merck-Moderna mRNA cancer vaccine (intismeran autogene) paired with Keytruda have reinforced their longstanding 2016 collaboration agreement, including Merck’s 2022 exercise of a $250 million joint-development option, rather than signaling any shift toward full ownership. Merck has pursued separate acquisitions such as Terns Pharmaceuticals and Verona Pharma to offset upcoming Keytruda patent losses and reach its $70 billion mid-2030s revenue target, while Moderna maintains independent operations amid its recent market-cap surge. With no regulatory filings, board disclosures, or strategic announcements indicating a 2026 deal, trader consensus prices the “No” outcome at 80.5% implied probability, reflecting the distinction between deepened partnership economics and outright M&A.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$20วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Recent positive Phase 3 results for the Merck-Moderna mRNA cancer vaccine (intismeran autogene) paired with Keytruda have reinforced their longstanding 2016 collaboration agreement, including Merck’s 2022 exercise of a $250 million joint-development option, rather than signaling any shift toward full ownership. Merck has pursued separate acquisitions such as Terns Pharmaceuticals and Verona Pharma to offset upcoming Keytruda patent losses and reach its $70 billion mid-2030s revenue target, while Moderna maintains independent operations amid its recent market-cap surge. With no regulatory filings, board disclosures, or strategic announcements indicating a 2026 deal, trader consensus prices the “No” outcome at 80.5% implied probability, reflecting the distinction between deepened partnership economics and outright M&A.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย